-
3,5-disubstituted-3H-imidazo[4,5-b]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases
申请人:Rhizen Pharmaceuticals SA
公开号:US11066402B2
公开(公告)日:2021-07-20
The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of c-Met kinase mediated disease or disorders with them.
本发明提供了可用作 c-Met 蛋白激酶调节剂的化合物、制备它们的方法、含有它们的药物组合物以及用它们治疗、预防和/或改善 c-Met 激酶介导的疾病或紊乱的方法。
-
[EN] NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES<br/>[FR] NOUVEAUX COMPOSÉS 3,5-DISUBSTITUÉS-3H-IMIDAZO[4,5-B]PYRIDINES ET 3,5-DISUBSTITUÉS-3H-[1,2,3]TRIAZOLO[4,5-B]PYRIDINES EN TANT QUE MODULATEURS DES PROTÉINES KINASES C-MET
申请人:RHIZEN PHARMACEUTICALS SA
公开号:WO2013144737A3
公开(公告)日:2013-12-05
-
NOVEL 3,5-DISUBSTITUED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUED -3H-[1,2,3]TRIAZOLO[4,5-B]PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES
申请人:Rhizen Pharmaceuticals S.A.
公开号:EP2831073A2
公开(公告)日:2015-02-04
-
NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED-3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES
申请人:Rhizen Pharmaceuticals SA
公开号:US20180072721A1
公开(公告)日:2018-03-15
The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of c-Met kinase mediated disease or disorders with them.
-
NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES
申请人:Rhizen Pharmaceuticals SA
公开号:US20210371416A1
公开(公告)日:2021-12-02
The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of c-Met kinase mediated disease or disorders with them.